The present disclosure relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40 and a PD-L1 antibody and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.